title: Current and Evolving Treatments of Genotype 1 Hepatitis C Virus.
abstract: Development of antiviral agents that target the hepatitis C virus (HCV) has improved the success and tolerability of treatment, especially for patients with HCV genotype 1 infection. The new treatment options mean that clinicians are better able to prevent complications from chronic HCV infection. The field of direct-acting antiviral therapies for HCV infection continues to advance at a rapid pace, and many more potential treatment regimens are being investigated. This article presents a summary of the current treatments available for patients infected with HCV genotype 1 and looks ahead to those that may play a role in the future.
authors.affiliation: Department of Medicine, The Johns Hopkins Hospital, 1830 East Monument Street, Suite 427, Baltimore, MD 21287, USA. Electronic address: salqaht1@jhmi.edu.
authors.forename: Saleh
authors.initials: S
authors.lastname: Alqahtani
authors.affiliation: Department of Medicine, The Johns Hopkins Hospital, 1830 East Monument Street, Suite 427, Baltimore, MD 21287, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Sulkowski
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004347:Drug Interactions; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans
chemical_list: D000998:Antiviral Agents
keywords: Cirrhosis; Hepatitis; Hepatitis C; Ledipasvir antiviral; Simeprevir; Sofosbuvir